TREA

88028453 - F FACTOR BIOSCIENCE

Follow

Information

  • Trademark
  • 88028453
  • Serial Number
    88028453
  • Registration Number
    6008687
  • Filing Date
    July 06, 2018
    6 years ago
  • Registration Date
    March 10, 2020
    4 years ago
  • Transaction Date
    March 10, 2020
    4 years ago
  • Status Date
    March 10, 2020
    4 years ago
  • Published for Opposition Date
    June 18, 2019
    5 years ago
  • Location Date
    February 04, 2020
    4 years ago
  • First Use Anywhere Date
    November 19, 2019
    5 years ago
  • First Use In Commerce Date
    November 19, 2019
    5 years ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    BRADLEY, EVELYN W
  • Attorney Docket Number
    107541-0038
    Attorney Name
    Rachelle A. Dubow, Esq.
    Law Office Assigned Location Code
    L40
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
F FACTOR BIOSCIENCE
Case File Statements
  • CC0000: Color is not claimed as a feature of the mark.
  • D10000: "BIOSCIENCE"
  • DM0000: The mark consists of the stylized design of a letter "F" to the left of the stacked words "FACTOR BIOSCIENCE" in a stylized font.
  • GS0011: Biochemicals in the nature of synthetic RNA encoding natural or engineered nucleases, zinc-finger nucleases, meganucleases, nickases, and transcription activator-like effector nucleases for use in vivo and in vitro genetic engineering
  • GS0051: Pharmaceuticals for treating human and veterinary non-infectious diseases in the nature of inflammatory diseases, infectious diseases, vitamin B12 deficiency, degenerative joint diseases, sensory organ diseases, hereditary diseases, namely, genetic diseases in the nature of chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, psychological diseases and physiological diseases in the nature of heart disease; gene therapy products, namely, genetically engineered cells and tissues for medical purposes, specifically for transplant purposes; chemical reagents for medical and veterinary purposes; synthetic mRNA being nucleic acid sequences and chemical reagents for medical and veterinary purposes for correcting deficient or defective genes; cell therapy products, namely, pharmaceutical preparations for use in cell therapy for treatment of cancer; synthetic mRNA being nucleic acid sequences and related chemical reagents for medical and veterinary purposes for reprogramming cells; synthetic RNA encoding reprogramming factors, namely, pharmaceutical preparations for use in cell therapy for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease; products in the nature of pharmaceutical preparations for use in cell therapy for converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing, for treatment of wounded skin, cancer, chromosomal abnormalities, single gene defects, multifactorial and teratogenic conditions, idiopathic intracranial hypertension, aesthetic skin diseases, traumatic brain injury, and heart disease
  • GS0091: Gene therapy technology in the nature of downloadable software for gene-editing that uses de novo-engineered gene-editing proteins expressed with synthetic mRNA; cell therapy products, namely, cell reprogramming technology in the nature of instruments for scientific laboratory research that use reprogramming factors expressed with synthetic mRNA, namely, cell-culture instruments in the nature of cell incubators, cell transfection instruments, and cell imaging instruments
  • GS0421: Pharmaceutical research and development services; pharmaceutical research and development services in the field of production of cell therapies, with or without gene-editing and with or without mRNA engineering; pharmaceutical research and development services in the field of, gene editing, mRNA engineering, cell reprogramming and cell therapy development; scientific laboratory services, in the field of stem cell production; scientific laboratory services in the field of production of stem cells and converting non-pluripotent cells into pluripotent stem cells, with or without gene-editing; scientific laboratory services in the field of gene-editing
  • PM0001: FACTOR FACTOR BIOSCIENCE
Case File Event Statements
  • 3/10/2020 - 4 years ago
    29 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 2/5/2020 - 4 years ago
    28 - NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Type: SUNA
  • 2/4/2020 - 4 years ago
    27 - ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Type: CNPR
  • 12/29/2019 - 4 years ago
    26 - STATEMENT OF USE PROCESSING COMPLETE Type: SUPC
  • 12/18/2019 - 4 years ago
    25 - USE AMENDMENT FILED Type: IUAF
  • 12/29/2019 - 4 years ago
    24 - CASE ASSIGNED TO INTENT TO USE PARALEGAL Type: AITU
  • 12/18/2019 - 4 years ago
    23 - TEAS STATEMENT OF USE RECEIVED Type: EISU
  • 8/13/2019 - 5 years ago
    22 - NOA E-MAILED - SOU REQUIRED FROM APPLICANT Type: NOAM
  • 6/18/2019 - 5 years ago
    21 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 6/18/2019 - 5 years ago
    20 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 5/29/2019 - 5 years ago
    19 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 5/10/2019 - 5 years ago
    18 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 5/9/2019 - 5 years ago
    17 - EXAMINER'S AMENDMENT ENTERED Type: XAEC
  • 5/9/2019 - 5 years ago
    16 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN
  • 5/9/2019 - 5 years ago
    15 - EXAMINERS AMENDMENT E-MAILED Type: GNEA
  • 5/9/2019 - 5 years ago
    14 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA
  • 4/10/2019 - 5 years ago
    13 - NOTIFICATION OF FINAL REFUSAL EMAILED Type: GNFN
  • 4/10/2019 - 5 years ago
    12 - FINAL REFUSAL E-MAILED Type: GNFR
  • 4/10/2019 - 5 years ago
    11 - FINAL REFUSAL WRITTEN Type: CNFR
  • 2/19/2019 - 5 years ago
    10 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 2/19/2019 - 5 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 2/18/2019 - 5 years ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 2/12/2019 - 5 years ago
    7 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 10/27/2018 - 6 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 10/27/2018 - 6 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 10/27/2018 - 6 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 10/25/2018 - 6 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 7/12/2018 - 6 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 7/10/2018 - 6 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP